Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ricolinostat + pomalidomide + dexamethasone
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy consisting of ricolinostat (ACY-1215), pomalidomide, and dexamethasone. Ricolinostat is a selective histone deacetylase 6 (HDAC6) inhibitor developed to enhance anti-myeloma activity when combined with other agents. Pomalidomide is an immunomodulatory agent that inhibits angiogenesis and myeloma cell growth, acting as a cereblon E3 ligase modulator. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties. This combination has been investigated in relapsed or refractory multiple myeloma, showing improved response rates compared to standard regimens[1][4][5].
- Other names
- ricolinostatpomalidomidedexamethasone
02
Targets
CRBN (Cereblon)GR (Glucocorticoid receptor)HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on ricolinostat + pomalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ricolinostat + pomalidomide + dexamethasone.